Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hypoxia-inducible Factor 1-α: A Key Regulator of Immune Checkpoint Receptors in Acute Myeloid Leukemia Cell Lines. | Iran J Allergy Asthma Immunol | 2026 | 42825905 | PubTator, text mining | PubMed |
| Targeting VISTA as a novel immunotherapy for skin cancer. | Front Immunol | 2026 | 42824772 | PubTator, text mining | PubMed |
| Thymic neuroendocrine tumours: molecular landscape, immune microenvironment and therapeutic perspectives. | Eur Respir Rev | 2026 | 42778205 | PubTator, text mining | PubMed |
| Molecular Architecture and Clinical Landscape of Immune Checkpoint Receptors and Ligands. | Antibodies (Basel) | 2026 | 42776797 | PubTator, text mining | PubMed |
| Comparative pathogenesis, tissue tropism, and immune dynamics of infectious bronchitis virus genotypes GI‑1 and GI‑24 in broiler chickens. | Poult Sci | 2026 | 42772140 | PubTator, text mining | PubMed |
| VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications. | Med Oncol | 2026 | 42742895 | PubTator, text mining | PubMed |
| Next-Generation Immune Checkpoint Inhibitors in Gastrointestinal Cancers: Mechanisms, Resistance, and Emerging Therapeutic Strategies. | Cancers (Basel) | 2026 | 42649907 | PubTator, text mining | PubMed |
| Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer. | Nat Commun | 2026 | 42649211 | PubTator, text mining | PubMed |
| Linoleic acid metabolic reprogramming is linked to immunometabolic remodeling and post-transplant recurrence risk in hepatocellular carcinoma. | Front Immunol | 2026 | 42643672 | PubTator, text mining | PubMed |
| Prognostic Significance of Tumor-Cell VISTA Expression on Survival Outcomes in Nivolumab-Treated Pleural Mesothelioma: The HOT1901 Retrospective Multi-Institutional Study. | Immunotargets Ther | 2026 | 42639079 | PubTator, text mining | PubMed |
| Inhibitory receptor states, immune homeostasis and the benefit-risk boundary of cancer checkpoint blockade. | Front Immunol | 2026 | 42625921 | PubTator, text mining | PubMed |
| HTS-Oracle X: AI-Guided Prospective Discovery of Small Molecule Immune Checkpoint Binders. | ACS Med Chem Lett | 2026 | 42621472 | PubTator, text mining | PubMed |
| A conserved grain-associated immunosuppressive niche in Sudanese patients with mycetoma. | PLoS Negl Trop Dis | 2026 | 42607090 | PubTator, text mining | PubMed |
| ARID1B mutations promote immune evasion in acute myeloid leukemia through upregulating VISTA expression. | Int Immunopharmacol | 2026 | 42600271 | PubTator, text mining | PubMed |
| Development of an immunocompetent cutaneous squamous cell carcinoma model identifies VISTA and CTLA-4 as targetable immune checkpoints. | J Immunother Cancer | 2026 | 42595354 | PubTator, text mining | PubMed |
| Role and clinical significance of VISTA (PD-1H) and PVR (CD155) expression in non-small cell lung carcinoma: a systematic review. | Transl Lung Cancer Res | 2026 | 42582713 | PubTator, text mining | PubMed |
| Macrophage VISTA restrains inflammatory and antigen-presenting programs during alloimmune tissue injury. | Int Immunopharmacol | 2026 | 42561669 | PubTator, text mining | PubMed |
| Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications. | Front Oncol | 2026 | 42558214 | PubTator, text mining | PubMed |
| Expression of LAG-3, TIM-3, and VISTA on Tumor-Infiltrating Lymphocytes in Advanced Laryngeal Squamous Cell Carcinoma and Their Association with CD8+ TIL Density. | Biomedicines | 2026 | 42512060 | PubTator, text mining | PubMed |
| Roles of V-domain Ig suppressor of T-cell activation-mediated immunoregulation in tumor immune escape (Review). | Oncol Lett | 2026 | 42491197 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers